Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCOGNITION: Piromelatine in mild Alzheimer's disease
NCT02615002Phase 2Completed
- Sponsor
- Neurim Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Piromelatine in Alzheimer's disease (AD), sponsored by Neurim Pharmaceuticals. Started Nov 2015; status: completed.
02
Drugs
Piromelatine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02615002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02615002.